<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1699-695X</journal-id>
<journal-title><![CDATA[Revista Clínica de Medicina de Familia]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Clin Med Fam]]></abbrev-journal-title>
<issn>1699-695X</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Española de Medicina de Familia y Comunitaria]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1699-695X2023000100010</article-id>
<article-id pub-id-type="doi">10.55783/rcmf.160110</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Alucinaciones secundarias a tratamiento en paciente con Parkinson]]></article-title>
<article-title xml:lang="en"><![CDATA[Hallucinations after treatment in a patient with Parkinson's]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rubio-López]]></surname>
<given-names><![CDATA[Juan María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Unidad de Residencias Jaén-Jaén Sur  ]]></institution>
<addr-line><![CDATA[Jaén ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2023</year>
</pub-date>
<volume>16</volume>
<numero>1</numero>
<fpage>58</fpage>
<lpage>60</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1699-695X2023000100010&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1699-695X2023000100010&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1699-695X2023000100010&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN La enfermedad de Parkinson (EP) se puede considerar como la segunda enfermedad neurodegenerativa en cuanto a prevalencia se refiere. La EP es una enfermedad de carácter crónico que evoluciona en fases consecutivas, con un diagnóstico inicial insidioso y de manejo complejo para el médico de Atención Primaria. En este artículo presentamos un caso de una interacción medicamentosa poco estudiada entre fármacos antidepresivos y antiparkinsonianos. La paciente acudió a revisión de neurología y, en un ajuste de medicación realizado por el compañero de neurología, se añadió rasalagina a su tratamiento habitual (levodopa/carbidopa) y ello creó a la paciente un cuadro de alucinaciones. Tras un estudio pormenorizado del caso, se llegó a la conclusión de que la rasalagina debía ser retirada y el cuadro neurológico de alucinaciones remitió.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT Parkinson's Disease (PD) can be deemed the second neurodegenerative disease in terms of prevalence. PD is a chronic disease that evolves in consecutive phases, with an insidious initial diagnosis and complex management for the primary care physician. In this paper we report a case of a poorly studied drug interaction between antidepressant and antiparkinsonian drugs. The patient went to a neurology review where, in a medication adjustment made by a neurology colleague, Rasalagin was added to her usual treatment (levodopa/carbidopa), which created hallucinations in the patient. After a minor case study, the conclusion was drawn that rasalagin should be withdrawn and the neurological picture of hallucinations remitted.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[alucinaciones]]></kwd>
<kwd lng="es"><![CDATA[interacciones medicamentosas]]></kwd>
<kwd lng="es"><![CDATA[depresión]]></kwd>
<kwd lng="es"><![CDATA[enfermedad de Parkinson]]></kwd>
<kwd lng="en"><![CDATA[Depression]]></kwd>
<kwd lng="en"><![CDATA[Drug Interactions]]></kwd>
<kwd lng="en"><![CDATA[Hallucinations]]></kwd>
<kwd lng="en"><![CDATA[Parkinson's Disease]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kempster]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Hurwitz]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Lees]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A new look at James Parkinson's Essay on the Shaking Palsy]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2007</year>
<volume>69</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>482-5</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Benito-León]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology of parkinson's disease in Spain and its contextualisation in the world]]></article-title>
<source><![CDATA[Rev Neurol]]></source>
<year>2018</year>
<volume>66</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>125-34</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Weintraub]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Morales]]></surname>
<given-names><![CDATA[KH]]></given-names>
</name>
<name>
<surname><![CDATA[Moberg]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bilker]]></surname>
<given-names><![CDATA[WB]]></given-names>
</name>
<name>
<surname><![CDATA[Balderston]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Duda]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antidepressant studies in Parkinson's disease: A review and meta-analysis]]></article-title>
<source><![CDATA[Mov Disord]]></source>
<year>2005</year>
<volume>20</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1161-9</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Naranjo]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Busto]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Sellers]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Sandor]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A method for estimating the probability of adverse drug reactions]]></article-title>
<source><![CDATA[Clin Pharmacol Ther]]></source>
<year>1981</year>
<volume>30</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>239-45</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Siderowf]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Stern]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Shoulson]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Kieburtz]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Oakes]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Day]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study]]></article-title>
<source><![CDATA[Arch Neurol]]></source>
<year>2002</year>
<volume>59</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1937-43</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aarsland]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Marsh]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Schrag]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neuropsychiatric symptoms in Parkinson's disease]]></article-title>
<source><![CDATA[Mov Disord]]></source>
<year>2009</year>
<volume>24</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>2175-86</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rankin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cadogan]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Patterson]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Kerse]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Cardwell]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
<name>
<surname><![CDATA[Bradley]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Interventions to improve the appropriate use of polypharmacy for older people]]></article-title>
<source><![CDATA[Cochrane Database of Systematic Reviews]]></source>
<year>2018</year>
<volume>2018</volume>
<numero>9</numero>
<issue>9</issue>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
